This invention discloses a novel combination that selectively targets MEIS proteins (MEIS1/2/3), key regulators of hematopoietic stem cell (HSC) self renewal and proliferation. The formulation contains cell permeable, intracellularly active small molecule MEIS inhibitors (MEISi 1, MEISi 2), hematopoietic growth factors (SCF, Flt3L, TPO), and optimized culture components.

Proven Results:
Proven Results Key findings from ex vivo and in vivo studies:

• Up to 2–10 Fold Expansion: In human cord blood, bone marrow, and murine HSCs.
• ≥5 Fold Increase: In functional colony formation.
• Reduced Expression: Of p21, HIF1α, and HIF2α.

Potential Applications:

This approach can enhance cell dose and engraftment success in HSC transplantation and opens therapeutic avenues in cancer therapy and regenerative medicine.